10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2017 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 20, 2018) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Revenue | $ 22,871,300 | 21,222,100 | 19,958,700 |
| Costs, expenses, and other: | |||
| Cost of sales | 6,070,200 | 5,654,900 | 5,037,200 |
| Research and development | 5,281,800 | 5,243,900 | 4,796,400 |
| Marketing, selling, and administrative | 6,588,100 | 6,452,000 | 6,533,000 |
| Acquired in-process research and development (Notes 3 and 4) | 1,112,600 | 30,000 | 535,000 |
| Asset impairment, restructuring, and other special charges (Note 5) | 1,673,600 | 382,500 | 367,700 |
| Othernet, (income) expense (Note 17) | (52,400) | 84,800 | (100,600) |
| Cost of sales, operating expenses, and other-net | 20,673,900 | 17,848,100 | 17,168,700 |
| Income before income taxes | 2,197,400 | 3,374,000 | 2,790,000 |
| Income taxes (Note 13) | 2,401,500 | 636,400 | 381,600 |
| Net income (loss) | (204,100) | 2,737,600 | 2,408,400 |
| Earnings (loss) per share: | |||
| Basic (usd per share) | (0.19) | 2.59 | 2.27 |
| Diluted (usd per share) | (0.19) | 2.58 | 2.26 |
| Shares used in calculation of earnings (loss) per share: | |||
| Basic (shares) | 1,052,023 | 1,058,324 | 1,061,913 |
| Diluted (shares) | 1,052,023 | 1,061,825 | 1,065,720 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2017 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 20, 2018) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Net income (loss) | $ (204,100) | 2,737,600 | 2,408,400 |
| Other comprehensive income (loss): | |||
| Change in foreign currency translation gains (losses) | 501,900 | (436,400) | (859,800) |
| Change in net unrealized gains and losses on securities | (181,300) | 303,000 | (138,100) |
| Change in defined benefit pension and retiree health benefit plans (Note 14) | (576,600) | (512,800) | 572,900 |
| Change in effective portion of cash flow hedges | 27,800 | 11,700 | (42,000) |
| Other comprehensive income (loss) before income taxes | (228,200) | (634,500) | (467,000) |
| Benefit (provision) for income taxes related to other comprehensive income (loss) items | 402,700 | (10,600) | (121,900) |
| Net other comprehensive income (loss) | 174,500 | (645,100) | (588,900) [1] |
| Comprehensive income (loss) | (29,600) | 2,092,500 | 1,819,500 |
| [1] Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to non-controlling interest. Other comprehensive income in 2017 consists of $199.0 million of other comprehensive income attributable to controlling interest and $24.5 million of other comprehensive loss attributable to non-controlling interest. | |||
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2017 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 20, 2018) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Net Cash Provided by Operating Activities [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income (loss) | $ (204,100) | 2,737,600 | 2,408,400 |
| Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities: | |||
| Depreciation and amortization | 1,567,300 | 1,496,600 | 1,427,700 |
| Change in deferred income taxes | (787,900) | 439,500 | (748,400) |
| Stock-based compensation expense | 281,300 | 255,300 | 217,800 |
| Acquired in-process research and development | 1,112,600 | 30,000 | 535,000 |
| Other non-cash operating activities, net | 441,500 | 376,100 | 263,300 |
| Other changes in operating assets and liabilities, net of acquisitions and divestitures: | |||
| Receivables(increase) decrease | (357,000) | (709,400) | (304,500) |
| Inventories(increase) decrease | (253,900) | (328,200) | (736,300) |
| Other assets(increase) decrease | (590,100) | (265,500) | (288,500) |
| Income taxes payableincrease (decrease) | 3,489,600 | (304,800) | (17,800) |
| Accounts payable and other liabilitiesincrease (decrease) | 916,300 | 1,123,800 | 207,900 |
| Net Cash Provided by Operating Activities | 5,615,600 | 4,851,000 | 2,964,600 |
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,076,800) | (1,037,000) | (1,066,200) |
| Disposals of property and equipment | 40,700 | 73,400 | 92,600 |
| Cash released for pending acquisition (Note 3) | 0 | 0 | 5,405,600 |
| Proceeds from sales and maturities of short-term investments | 4,852,500 | 1,642,000 | 2,161,800 |
| Purchases of short-term investments | (3,389,700) | (1,327,400) | (842,200) |
| Proceeds from sales of noncurrent investments | 2,586,000 | 2,086,000 | 3,068,400 |
| Purchases of noncurrent investments | (4,611,600) | (4,346,000) | (3,226,500) |
| Proceeds from sale of product rights | 0 | 0 | 410,000 |
| Purchases of in-process research and development | (1,086,800) | (55,000) | (560,000) |
| Cash paid for acquisitions, net of cash acquired (Note 3) | (882,100) | (45,000) | (5,283,100) |
| Other investing activities, net | (215,800) | (130,100) | (133,600) |
| Net Cash Provided by (Used for) Investing Activities | (3,783,600) | (3,139,100) | 26,800 |
| Cash Flows from Financing Activities | |||
| Dividends paid | (2,192,100) | (2,158,500) | (2,127,300) |
| Net change in short-term borrowings | 1,397,500 | 1,293,200 | (2,680,600) |
| Proceeds from issuance of long-term debt | 2,232,000 | 1,206,600 | 4,454,700 |
| Repayments of long-term debt | (630,600) | (200) | (1,955,700) |
| Purchases of common stock | (299,800) | (600,100) | (749,500) |
| Other financing activities, net | (364,400) | (300,800) | (52,600) |
| Net Cash Provided by (Used for) Financing Activities | 142,600 | (559,800) | (3,111,000) |
| Effect of exchange rate changes on cash and cash equivalents | (20,500) | (236,400) | (85,600) |
| Net increase (decrease) in cash and cash equivalents | 1,954,100 | 915,700 | (205,200) |
| Cash and cash equivalents at beginning of year | 4,582,100 | 3,666,400 | |
| Cash and Cash Equivalents at End of Year | 6,536,200 | 4,582,100 | 3,666,400 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ELI LILLY & CO | ||
Ticker: LLY Fiscal Year: 2017 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2017 10-K (Filed: Feb 20, 2018) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2017 | Dec 31, 2016 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents (Note 7) | $ 6,536,200 | 4,582,100 |
| Short-term investments (Note 7) | 1,497,900 | 1,456,500 |
| Accounts receivable, net of allowances of $38.7 (2017) and $40.3 (2016) | 4,546,300 | 4,029,400 |
| Other receivables | 715,900 | 736,900 |
| Inventories (Note 6) | 4,458,300 | 3,561,900 |
| Prepaid expenses and other | 1,447,500 | 734,600 |
| Total current assets | 19,202,100 | 15,101,400 |
| Other Assets | ||
| Investments (Note 7) | 5,678,800 | 5,207,500 |
| Goodwill (Note 8) | 4,370,100 | 3,972,700 |
| Other intangibles, net (Note 8) | 4,029,200 | 4,357,900 |
| Sundry | 2,874,300 | 1,913,800 |
| Total other assets | 16,952,400 | 15,451,900 |
| Property and equipment, net (Note 9) | 8,826,500 | 8,252,600 |
| Total assets | 44,981,000 | 38,805,900 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt (Note 10) | 3,706,600 | 1,937,400 |
| Accounts payable | 1,410,700 | 1,349,300 |
| Employee compensation | 997,900 | 896,900 |
| Sales rebates and discounts | 4,465,100 | 3,914,900 |
| Dividends payable | 590,600 | 548,100 |
| Income taxes payable (Note 13) | 532,900 | 119,100 |
| Other current liabilities | 2,832,100 | 2,220,900 |
| Total current liabilities | 14,535,900 | 10,986,600 |
| Other Liabilities | ||
| Long-term debt (Note 10) | 9,940,500 | 8,367,800 |
| Accrued retirement benefits (Note 14) | 3,513,900 | 2,453,900 |
| Long-term income taxes payable (Note 13) | 3,776,500 | 688,900 |
| Other noncurrent liabilities | 1,546,300 | 2,228,200 |
| Total other liabilities | 18,777,200 | 13,738,800 |
| Eli Lilly and Company Shareholders' Equity (Notes 11 and 12) | ||
| Common stockno par value Authorized shares: 3,200,000 Issued shares: 1,100,672 (2017) and 1,101,586 (2016) | 687,900 | 688,500 |
| Additional paid-in capital | 5,817,800 | 5,640,600 |
| Retained earnings | 13,894,100 | 16,046,300 |
| Employee benefit trust | (3,013,200) | (3,013,200) |
| Accumulated other comprehensive loss (Note 16) | (5,718,600) | (5,274,000) |
| Cost of common stock in treasury | (75,800) | (80,500) |
| Total Eli Lilly and Company shareholders' equity | 11,592,200 | 14,007,700 |
| Noncontrolling interests | 75,700 | 72,800 |
| Total equity | 11,667,900 | 14,080,500 |
| Total liabilities and equity | 44,981,000 | 38,805,900 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |